Recent progress in GM-CSF-based cancer immunotherapy

Immunotherapy

Volumn 9, Issue 4, 2017, Pages 347-360

  Yan, Wan Lun ^a,b   Shen, Kuan Yin ^c,d   Tien, Chun Yuan ^a,b   Chen, Yu An ^d   Liu, Shih Jen ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cancer immunotherapy; GM CSF; vaccine

Indexed keywords

CANCER VACCINE; DNA VACCINE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IPILIMUMAB; MITUMPROTIMUT T; MONTANIDE ISA 51; ONCOLYTIC HERPES VIRUS; OXALIPLATIN; PLACEBO; PREDNISONE; SARGRAMOSTIM; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; EVENT FREE SURVIVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OSTEOSARCOMA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; TUMOR IMMUNITY; ANIMAL; CARCINOGENESIS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRENDS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; CANCER VACCINES; CARCINOGENESIS; CELL DIFFERENTIATION; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VACCINES, DNA;

EID: 85015727480     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0141     Document Type: Review

References (88)

1. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta. Med. Scand. Suppl. 276, 1-103 (1953).
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480(7378), 480-489 (2011).
3. Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 206(9), 1853-1862 (2009).
4. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
5. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000).
6. Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114(7), 1289-1298 (2009).
7. Hercus TR, Dhagat U, Kan WL, et al. Signalling by the ?c family of cytokines. Cytokine Growth Factor Rev. 24(3), 189-201 (2013).
8. Metcalf D. Hematopoietic cytokines. Blood 111(2), 485-491 (2008).
9. Metcalf D. The colony-stimulating factors and cancer. Nat. Rev. Cancer 10(6), 425-434 (2010).
10. Daro E, Pulendran B, Brasel K, et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165(1), 49-58 (2000).
11. Vremec D, Lieschke GJ, Dunn AR, Robb L, Metcalf D, Shortman K. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur. J. Immunol. 27(1), 40-44 (1997).
12. King IL, Kroenke MA, Segal BM. GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J. Exp. Med. 207(5), 953-961 (2010).
13. Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45(5), 963-973 (2016).
14. Van De Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119(15), 3383-3393 (2012).
15. Liu Y, Xiao L, Joo KI, Hu B, Fang J, Wang P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules 15(10), 3836-3845 (2014).
16. Kim J, Li WA, Choi Y, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat. Biotechnol. 33(1), 64-72 (2015).
17. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17(11), 3520-3526 (2011).
18. Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl Cancer Inst. 106(11), dju268 (2014).
19. Murtaza A, Kuchroo VK, Freeman GJ. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int. Immunol. 11(3), 407-416 (1999).
20. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167(6), 3114-3122 (2001).
21. Ruff MR, Farrar WL, Pert CB. Interferon gamma and granulocyte/macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 83(17), 6613-6617 (1986).
22. Yamashita Y, Nara N, Aoki N. Antiproliferative and differentiative effect of granulocyte-macrophage colony-stimulating factor on a variant human small-cell lung cancer cell line. Cancer Res. 49(19), 5334-5338 (1989).
23. Urdinguio RG, Fernandez AF, Moncada-Pazos A, et al. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 73(1), 395-405 (2013).
24. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18(8), 1614-1621 (2000).
25. Spitler LE, Weber RW, Allen RE, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, IV melanoma. J. Immunother. 32(6), 632-637 (2009).
26. Lawson DH, Lee S, Zhao F, et al. Randomized, placebo-controlled, Phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J. Clin. Oncol. 33(34), 4066-4076 (2015).
27. Nasi ML, Lieberman P, Busam KJ, et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell. Mol. Ther. 5(3), 139-144 (1999).
28. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2(4), 324-329 (2000).
29. Chou J, Roizman B. The gamma 1(34. 5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl Acad. Sci. USA 89(8), 3266-3270 (1992).
30. Liu BL, Robinson M, Han ZQ, et al. ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, anti-tumour properties. Gene Ther. 10(4), 292-303 (2003).
31. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375(6530), 415-418 (1995).
32. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77(4), 525-535 (1994).
33. Hu JC, Coffin RS, Davis CJ, et al. A Phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12(22), 6737-6747 (2006).
34. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33(25), 2780-2788 (2015).
35. Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J. Immunother. Cancer 2, 11 (2014).
36. Collichio FA, Amatruda T, Senzer NN, et al. OPTiM: a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. 31(18 Suppl. ), LBA9008 (2013).
37. Nelson D, Fisher S, Robinson B. The 'Trojan Horse' approach to tumor immunotherapy: targeting the tumor microenvironment. J. Immunol. Res. 2014, 789069 (2014).
38. Markovic SN, Suman VJ, Nevala WK, et al. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am. J. Clin. Oncol. 31(6), 573-579 (2008).
39. Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clin. Cancer Res. 16(15), 4024-4030 (2010).
40. Ali OA, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1(8), 8ra19 (2009).
41. Zarei S, Schwenter F, Luy P, et al. Role of GM-CSF signaling in cell-based tumor immunization. Blood 113(26), 6658-6668 (2009).
42. Reardon DA, Wucherpfennig KW, Freeman G, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev. Vaccines 12(6), 597-615 (2013).
43. Joshi VB, Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev. Vaccines 13(1), 9-15 (2014).
44. Vonka V, Petrackova M. Immunology of chronic myeloid leukemia: current concepts and future goals. Expert Rev. Clin. Immunol. 11(4), 511-522 (2015).
45. Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol. 19(3), 176-183 (1996).
46. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin. Cancer Res. 16(1), 338-347 (2010).
47. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, immune activation. Ann. Surg. 253(2), 328-335 (2011).
48. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. 10(4), 799-816 (2004).
49. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 13(6), 555-562 (2006).
50. Lipson EJ, Sharfman WH, Chen S, et al. Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med. 13, 214 (2015).
51. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 16(4), 304-310 (2010).
52. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007).
53. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5), 975-984 (2008).
54. Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11(9), 509-524 (2014).
55. Zandberg DP, Rollins S, Goloubeva O, et al. A Phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol. Immunother. 64(3), 367-379 (2015).
56. Gameiro SR, Jammeh ML, Hodge JW. Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev. Vaccines 12(6), 617-629 (2013).
57. He Y, Hong Y, Mizejewski GJ. Engineering alpha-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy 6(6), 725-736 (2014).
58. Ohue Y, Eikawa S, Okazaki N, et al. Spontaneous antibody, CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small-cell lung cancer patients. Int. J. Cancer 131(5), E649-658 (2012).
59. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 74(11), 2907-2912 (2014).
60. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193(1), 73-88 (2001).
61. De Pas T, Giovannini M, Rescigno M, et al. Vaccines in non-small-cell lung cancer: rationale, combination strategies and update on clinical trials. Crit. Rev. Oncol. Hematol. 83(3), 432-443 (2012).
62. Wen Q, Xiong W, He J, et al. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions. J. Transl. Med. 14, 41 (2016).
63. Li M, Wang B, Wu Z, et al. A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma. Tumour Biol. 36(7), 5497-5503 (2015).
64. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362(6422), 755-758 (1993).
65. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
66. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27(18), 3036-3043 (2009).
67. Muraro E, Martorelli D, Dolcetti R. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Hum. Vaccin. Immunother. 9(5), 1078-1083 (2013).
68. Cassaday RD, Sondel PM, King DM, et al. A Phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin. Cancer Res. 13(2 Pt 1), 540-549 (2007).
69. Perales MA, Yuan J, Powel S, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol. Ther. 16(12), 2022-2029 (2008).
70. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, Mcneel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J. Immunother. 33(6), 639-647 (2010).
71. Hodi FS, O'day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
72. Hodi FS, Lee S, Mcdermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312(17), 1744-1753 (2014).
73. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116(7), 1935-1945 (2006).
74. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4717 (2003).
75. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 16(7), 795-803 (2015).
76. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GM-CSF. J. Clin. Invest. 117(7), 1902-1913 (2007).
77. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123(1), 39-49 (2010).
78. Dufait I, Schwarze JK, Liechtenstein T, et al. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget 6(14), 12369-12382 (2015).
79. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18(2), 226-232 (2007).
80. Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin. Cancer Res. 15(22), 7036-7044 (2009).
81. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin. Cancer Res. 15(22), 7029-7035 (2009).
82. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
83. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713-6721 (2005).
84. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
85. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16(18), 4583-4594 (2010).
86. Annels NE, Shaw VE, Gabitass RF, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol. Immunother. 63(2), 175-183 (2014).
87. Locke F, Clark JI, Gajewski TF. A Phase II study of oxaliplatin, docetaxel, GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother. Pharmacol. 65(3), 509-514 (2010).
88. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J. Clin. Invest. 126(3), 799-808 (2016).